SLC5A2 and diabetes mellitus: The use of novel classes of diabetes medications, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose transporter-2 (SGLT-2) inhibitors, has been associated with cardiovascular benefits.